Contribution of insertions and deletions to the variability of hepatitis C virus populations

Journal of General Virology

Volumn 88, Issue 8, 2007, Pages 2198-2203

  Torres Puente, Manuela ^a   Cuevas, José M ^a   Jiménez Hernández, Nuria ^a   Bracho, María A ^a   García Robles, Inmaculada ^a   Carnicer, Fernando ^b   del Olmo, Juan ^c   Ortega, Enrique ^d   Moya, Andrés ^a   González Candelas, Fernando ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC SELECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS GENOME;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENE DELETION; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; RIBAVIRIN; SEQUENCE ALIGNMENT; SPAIN; SPECIES SPECIFICITY; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 34547591765     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82855-0     Document Type: Article

References (49)

1. Abe, K., Inch auspe, G. & Fujisawa, K. (1992). Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J Gen Virol 73, 2725-2729.
2. Afdhal, N. H. (2004). The natural history of hepatitis C. Semin Liver Dis 24 (Suppl. 2), 3-8.
3. Akuta, N., Suzuki, F., Kawamura, Y, Yatsuji, H., Sezaki, H, Suzuki, Y., Hosaka, T., Kobayashi, M., Kobayashi, M. & other authors (2007). Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46, 403-410.
4. Bracho, M. A., García-Robles, I., Jiménez, N., Torres-Puente, M., Moya, A. & González-Candelas, F. (2004). Effect of oligonucleotide primers in determining viral variability within hosts. Virol J 1, 13.
5. Brillanti, S., Garson, J., Foil, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M. & Barbara, L. (1994). A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
6. Casino, C., McAllister, J., Davidson, F., Power, J., Lawlor, E., Yap, P. L., Simmonds, P. & Smith, D. B. (1999). Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. J Gen Virol 80, 717-725.
7. Castelain, S., Bonte, D., Penin, F., Francois, C., Capron, D., Dedeurwaerder, S., Zawadzki, P., Morel, V., Wychowski, C. & Duverlie, G. (2007). Hepatitis C virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol 79, 144-154.
8. Chamberlain, R. W., Adams, N. J., Taylor, L. A., Simmonds, P. & Elliott, R. M. (1997). The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236, 44-49.
9. Curran, R., Jameson, C. L., Craggs, J. K., Grabowska, A. M., Thomson, B. J., Robins, A., Irving, W. L. & Ball, J. K. (2002). Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 83, 11-23.
10. Dienstag, J. L. & McHutchison, J. G. (2006) American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130, 231-264.
11. Durante Mangoni, E., Forton, D. M., Ruggiero, G. & Karayiannis, P. (2003). Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-α preparations. J Med Virol 70, 62-73.
12. Duverlie, G., Khorsi, H., Castelain, S., Jaillon, O., Izopet J., Lunel, F., Eb, F., Penin, F. & Wychowsid, C. (1998). Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79, 1373-1381.
13. Eigen, M. & Biebricher, C. K. (1988). Sequence space and quasispecies distribution. In Variability of RNA Genomes, pp. 211-245. Edited by E. Domingo, J. J. Holland & P. Ahlquist. Boca Raton, FL: CRC Press.
14. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F. & Sato, C. (1996). Mutations in the nonstructural. protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334, 77-81.
15. Farci, P., Shimoda, A., Colana, A., Diaz, G, Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J. & other authors (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339-344.
16. Farci, P., Strazzera, R., Alter, H. J., Farci, S., Degioannis, D., Coiana, A., Peddis, G., Usai, F., Serra, G. & other authors (2002). Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 99, 3081-3086.
17. Farci P., Quinti, I., Farci, S., Alter, H. J., Strazzera, R., Palomba, E., Coiana, A., Cao, D., Casadei, A. M. & other authors (2006). Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A 103, 8475-8480.
18. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr, Haussinger, D., Diago, M., Carosi, G. & other authors (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
19. Gale, M. J., Jr, Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227.
20. Gale, M. J., Jr, Korth, M. J. & Katze, M. G. (1998). Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10, 157-162.
21. Gerotto, M., Dal Pero, F., Loffreda, S., Bianchi, F. B., Alberti, A. & Lenzi, M. (2001). A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinernia type 2. Blood 98, 2657-2663.
22. Heathcote, J. & Main, J. (2005). Treatment of hepatitis C. J Viral Hepat 12, 223-235.
23. Hohne, M., Schreier, E. & Roggendorf, M. (1994). Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol 137, 25-34.
24. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park Y. & Jones, E. A. (1986). Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315, 1575-1578.
25. Jiménez-Hernández, N., Torres-Puente, M., Bracho, M. A., García-Robles, I., Ortega, E., del Olmo, J., Carnicer, F., González-Candelas, F. & Moya, A. (2007). Epidemic dynamics of two coexisting hepatitis C virus subtypes. J Gen Virol 88, 123-133.
26. Kato, N., Ootsuyama, Y., Tanaka, T., Nakagawa, M., Nakazawa, T., Muraiso, K., Ohkoshi, S., Hijikata, M. & Shimotohno, K. (1992). Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 22, 107-123.
27. Kuiken, C., Combat, C., Bukh, J., Shin-i, T., Deleage, G., Mizokami, M., Richardson, R. L., Sablon, E., Yusim, K. & other authors (2006). A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44, 1355-1361.
28. Lindenbach, B. D. & Rice, C. M. (2005). Unravelling hepatitis C virus replication from genome to function. Nature 436, 933-938.
29. Liu, S., Ansari, I. H., Das, S. C. & Pattnaik, A. K. (2006). Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. J Gen Virol 87, 323-327.
30. Maertens, G. S. L. (1997). Genotypes and genetic variation of hepatitis C virus. In The Molecular Medicine of Viral Hepatitis. Edited by T. J. Harrison & A. J. Zuckerman. New York: John Wiley.
31. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
32. Manzin, A., Solforosi, L., Petrelli, E., Macarri, G., Tosone, G., Piazza, M. & Clementi, M. (1998). Evolution of hypervariable region 1 of hepatitis C virus in primary infections. J Virol 72, 6271-6276.
33. Pawlotsky, J. M. (2006). Therapy of hepatitis C: from empiricism to eradication. Hepatology 43, S207-S220.
34. Penin, F., Combet, C., Germanidis, G., Frainais, P. O., Deleage, G. & Pawlotsky, J. M. (2001). Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75, 5703-5710.
35. Polyak, S. J., Faulkner, G., Carithers, R. L., Jr, Corey, L. & Gretch, D. R. (1997). Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 175, 1101-1107.
36. Ray, S. C., Wang, Y. M., Laeyendecker, O., Ticehurst, J. R., Villano, S. A. & Thomas, D. L (1999). Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73, 2938-2946.
37. Reed, K. E. & Rice, C. M. (2000). Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242, 55-84.
38. Revie, D., Alberti, M. O., Braich, R. S., Bayles, D., Prichard, J. G. & Salahuddin, S. Z. (2006). Discovery of significant variants containing large deletions in the 5'UTR of huMan hepatitis C virus (HCV). Virol J 3, 82.
39. Shepard, C. W., Finelli, L. & Alter, M. J.(2005). Global epidemiology of hepatitis C virus infection. Lancet Infect Vis 5, 558-567.
40. Staden, R., Beal, K. F. & Bonfield, J. K. (2000). The Staden package, 1998. Methods Mol Biol 132, 115-130.
41. Thompson, J. D., Gibson, T. J., Plewniak F., Jeanmougin, F. & Higgins, D. G. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25, 4876-4882.
42. Torres-Puente, M. (2004). Variabilidad genética y respuesta al tratamiento antiviral en el virus de la Hepatitis C (VHC). PhD thesis, Universidad de Valencia.
43. Troesch, M., Meunier, L., Lapierre, P., Lapointe, N., Alvarez, F., Boucher, M. & Soudeyns, H. (2006). Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352, 357-367.
44. Vallet, S., Gouriou, S., Nkontchou, G., Hotta, H., Vilerio, M., Legrand-Quillien, M. C., Beaugrand, M., Trinchet J. C., Nousbaum, J. B. & other authors (2007). Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? J Viral Hepat 14, 96-106.
45. Wasley, A. & Alter, M. J. (2000). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20, 1-16.
46. Weiner, A. J., Brauer, M. J., Rosenblatt, J., Richman, K. H., Tung, J., Crawford, K., Bonino, F., Saracco, G., Choo, Q. L. & Houghton, M. (1991). Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180, 842-848.
47. Yagnik, A. T., Lahm, A., Meola, A., Roccasecca, R. M., Ercole, B. B., Nicosia, A. & Tramontano, A. (2000). A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40, 355-366.
48. Zekri, A. R., El Din, H. M., Bahnassy, A. A., Khaled, M. M., Omar, A., Fouad, I., El Hefnewi, M., Thakeb, F. & El Awady, M. (2007). Genetic distance and heterogeneity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J 4, 16.
49. Zhang, J., Yamada, O., Ito, T., Akiyama, M., Hashimoto, Y., Yoshida, H., Makino, R., Masago, A., Uemura, H. & Araki, H. (1999). A single nucleotide insertion in the 5′-untranslated region of hepatitis C virus leads to enhanced cap-independent translation. Virology 261, 263-270.